Please login to the form below

Not currently logged in

Novartis' patupilone fails phase III trial

Novartis has announced that its investigative compound, patupilone, has failed a phase III trial of patients with advanced ovarian cancer

Novartis has announced that its investigative compound, patupilone (EPO906), has failed a phase III trial of patients with advanced ovarian cancer, refractory or resistant to platinum-based therapy.

The compound was tested in a phase III study carried out in around 168 sites across 22 countries. The randomised study, which involved 829 patients with epithelial ovarian, primary fallopian or primary peritoneal cancer, compared patupilone with Doxil/Caelyx (pegylated liposomal doxorubicin).

The primary endpoint of the trial was overall survival. Secondary endpoints included progression-free survival, safety and overall response rate. Patupilone did not show a significant overall survival advantage. Based on this, Novartis does not plan to proceed with regulatory filings based on these data.

27th May 2010


Featured jobs

Subscribe to our email news alerts


Add my company
Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...
What do Healthcare Professionals think about the inclusion of remote selling techniques?
Evolving to a digitally focused pharma / healthcare company - an organisational roadmap...
Drug pricing and competition
Strengthening business competition and reducing anti-competitive practices
How the CMA is tackling high prices for essential drugs...